Suppression of homologous recombination sensitizes human tumor cells to IGF-1R inhibition

International Journal of Cancer

Volumn 136, Issue 12, 2015, Pages 2961-2966

  Lodhia, Kunal A ^a   Gao, Shan ^a   Aleksic, Tamara ^a   Esashi, Fumiko ^b   Macaulay, Valentine M ^a,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

biomarker; BRCA2; DNA repair; homologous recombination; IGF 1R inhibitor; RAD51; type 1 IGF receptor

Indexed keywords

AZ 12253801; BO 2; BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR; DNA; HISTONE H2AX; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAD51 PROTEIN; RECEPTOR BLOCKING AGENT; RO 3306; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; BORON DERIVATIVE; BORON OXIDE; BRCA1 PROTEIN; CYCLIN DEPENDENT KINASE 1; H2AFX PROTEIN, HUMAN; HISTONE; ISOXAZOLE DERIVATIVE; PTEN PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE; RAD51 PROTEIN, HUMAN; THIAZOLE DERIVATIVE;

ARTICLE; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; RECEPTOR BLOCKING; RECOMBINATION REPAIR; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; COLORECTAL TUMOR; DNA REPAIR; DRUG EFFECTS; FLUORESCENCE MICROSCOPY; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROSTATE TUMOR; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; BORON COMPOUNDS; BRCA1 PROTEIN; BRCA2 PROTEIN; CDC2 PROTEIN KINASE; CELL LINE, TUMOR; CELL SURVIVAL; COLORECTAL NEOPLASMS; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; HISTONES; HOMOLOGOUS RECOMBINATION; HUMANS; ISOXAZOLES; MALE; MICROSCOPY, FLUORESCENCE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; PYRIMIDINES; QUINOLINES; RAD51 RECOMBINASE; RECEPTOR, IGF TYPE 1; RNA INTERFERENCE; THIAZOLES;

EID: 84927556211     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29327     Document Type: Article

References (25)

1. Turner BC, Haffty BG, Narayanan L, et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 1997; 57: 3079-83.
2. Moreno-Acosta P, Gamboa O, Sanchez de Gomez M, et al. IGF1R gene expression as a predictive marker of response to ionizing radiation for patients with locally advanced HPV16-positive cervical cancer. Anticancer Res 2012; 32: 4319-25.
3. King H, Aleksic T, Haluska P, et al. Can we unlock the potential of IGF-1R inhibition in cancer therapy? Cancer Treat Rev 2014; 40: 1096-1105.
4. Rochester MA, Riedemann J, Hellawell GO, et al. Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther 2005; 12: 90-100.
5. Riesterer O, Yang Q, Raju U, et al. Combination of anti-IGF-1R antibody A12 and ionizing radiation in upper respiratory tract cancers. Int J Radiat Oncol Biol Phys 2011; 79: 1179-87.
6. Awasthi N, Zhang C, Ruan W, et al. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer. Mol Cancer Ther 2012; 11: 2644-53.
7. Ferte C, Loriot Y, Clemenson C, et al. IGF-1R targeting increases the antitumor effects of DNA damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy. Mol Cancer Ther 2013; 12: 1213-22.
8. Trojanek J, Ho T, Del Valle L, et al. Role of the insulin-like growth factor I/insulin receptor substrate 1 axis in Rad51 trafficking and DNA repair by homologous recombination. Mol Cell Biol 2003; 23: 7510-24.
9. Cosaceanu D, Budiu RA, Carapancea M, et al. Ionizing radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism. Oncogene 2007; 26: 2423-34.
10. Turney BW, Kerr M, Chitnis MM, et al. Depletion of the type 1 IGF receptor delays repair of radiation-induced DNA double strand breaks. Radiother Oncol 2012; 103: 402-9.
11. Chitnis MM, Lodhia KA, Aleksic T, et al. IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination. Oncogene 2014; 33: 5262-73.
12. Gao S, Bajrami I, Verrill C, et al. Dsh homolog DVL3 mediates resistance to IGF-1R inhibition by regulating IGF signaling to RAS. Cancer Res 2014; 74: 5866-77.
13. Helleday T,. Pathways for mitotic homologous recombination in mammalian cells. Mutat Res 2003; 532: 103-15.
14. Yuen JS, Cockman ME, Sullivan M, et al. The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma. Oncogene 2007; 26: 6499-508.
15. Lobrich M, Shibata A, Beucher A, et al. gammaH2AX foci analysis for monitoring DNA double-strand break repair: strengths, limitations and optimization. Cell Cycle 2010; 9: 662-9.
16. Tsuzuki T, Fujii Y, Sakumi K, et al. Targeted disruption of the Rad51 gene leads to lethality in embryonic mice. Proc Natl Acad Sci U S A 1996; 93: 6236-40.
17. Mendes-Pereira AM, Martin SA, Brough R, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009; 1: 315-22.
18. Phin S, Moore MW, Cotter PD,. Genomic Rearrangements of PTEN in Prostate Cancer. Front Oncol 2013; 3: 240.
19. Xu N, Lao Y, Zhang Y, et al. Akt: a double-edged sword in cell proliferation and genome stability. J Oncol 2012; 2012: 951724.
20. Esashi F, Christ N, Gannon J, et al. CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature 2005; 434: 598-604.
21. Yata K, Lloyd J, Maslen S, et al. Plk1 and CK2 act in concert to regulate Rad51 during DNA double strand break repair. Mol Cell 2012; 45: 371-83.
22. Hucl T, Rago C, Gallmeier E, et al. A syngeneic variance library for functional annotation of human variation: application to BRCA2. Cancer Res 2008; 68: 5023-30.
23. Budke B, Logan HL, Kalin JH, et al. RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells. Nucleic Acids Res 2012; 40: 7347-57.
24. Huang F, Mazina OM, Zentner IJ, et al. Inhibition of homologous recombination in human cells by targeting RAD51 recombinase. J Med Chem 2012; 55: 3011-20.
25. Johnson N, Li YC, Walton ZE, et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med 2011; 17: 875-82.